Novel Cancer Stem Marker and Its Applicability for Grading Primary Human Gliomas

Poorly differentiated cell populations including tumor-initiating stem cells have been demonstrated to display a unique ability to natively internalize fragmented double-stranded DNA. Using this feature as a marker, we show that 0.1% to 6% of human glioblastoma cells from the bioptates can effective...

Descripción completa

Detalles Bibliográficos
Autores principales: Dolgova, Evgeniya V., Mishinov, Sergey V., Proskurina, Anastasiya S., Potter, Ekaterina A., Efremov, Yaroslav R., Bayborodin, Sergey I., Tyrinova, Tamara V., Stupak, Vyacheslav V., Ostatin, Alexandr A., Chernykh, Elena R., Bogachev, Sergey S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789816/
https://www.ncbi.nlm.nih.gov/pubmed/29375020
http://dx.doi.org/10.1177/1533034617753812
Descripción
Sumario:Poorly differentiated cell populations including tumor-initiating stem cells have been demonstrated to display a unique ability to natively internalize fragmented double-stranded DNA. Using this feature as a marker, we show that 0.1% to 6% of human glioblastoma cells from the bioptates can effectively internalize a fluorescently labeled DNA probe. Of these, using samples from 3 patients, 66% to 100% cells are also positive for CD133, a well-established surface marker of tumor-initiating glioma stem cells. Using the samples from primary malignant brain lesions (33 patients), we demonstrate that tumor grading significantly correlates (R = .71) with the percentage of DNA-internalizing cells. No such correlation is observed for relapse samples (18 patients).

Ejemplares similares